Is Capivasertib associated with severe side effects?

Capivasertib (trade name: Truqap) is an oral pan-AKT inhibitor. In combination with fulvestrant, it is indicated for the treatment of locally advanced or metastatic hormone receptor-positive, HER2-negative breast cancer with specific gene mutations (PIK3CA/AKT1/PTEN).

Is Capivasertib associated with severe side effects?

Some side effects usually do not require medical attention and may disappear as your body adjusts to the medication during treatment. In addition, your doctor may advise you on ways to prevent or reduce some of these side effects. If any of the following side effects persist, are bothersome, or if you have any questions about them, consult your doctor:

Decreased appetite

Swelling or inflammation of the mouth

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your doctor.

Which patients may be eligible for capivasertib treatment?

You may be suitable for capivasertib treatment if you have locally advanced or metastatic breast cancer and meet the following criteria:

Estrogen receptor-positive;

HER2-negative;

And harbor one or more mutations in the PIK3CA, AKT1 or PTEN genes.

Prior to initiating capivasertib treatment, you should have received therapy with an aromatase inhibitor in combination with a CDK4/6 inhibitor (such as palbociclib, abemaciclib or ribociclib).

Capivasertib is not indicated for the treatment of primary breast cancer.

Testing for PIK3CA, AKT1 or PTEN gene mutations

Testing can be performed on estrogen receptor-positive, HER2-negative breast cancer tissue to determine the presence of PIK3CA, AKT1 or PTEN gene mutations.

Your treatment team may discuss with you performing a biopsy of your metastatic breast cancer lesions to detect these mutations. Alternatively, they may test a sample of your primary breast cancer tissue that was surgically removed and stored in a laboratory previously.

If you undergo a biopsy, the tissue sample will be sent to a laboratory for testing.

You may also undergo a blood test to screen for PIK3CA, AKT1 or PTEN gene mutations.

If your breast cancer has one or more mutations in the PIK3CA, AKT1 or PTEN genes, capivasertib treatment may be recommended.